fda drug shortages semaglutide injection status resolved 2025 Novo's Wegovy and Ozempic removed from US shortage list, compounders on notice FDA/Food, Drug & Device /

doi: 10.1111/josi.12542 38 BrochuPMGeorgiaEJJubranMRobbinsMWestKCrockerJet al

UHCs 2026 commercial formulary includes six GLP-1 medications: Wegovy (semaglutide for obesity and CVD), Zepbound (tirzepatide for obesity and OSA), Ozempic (semaglutide for type 2 diabetes), Mounjaro (tirzepatide for type 2 diabetes), Saxenda (liraglutide for obesity), and Rybelsus (oral semaglutide for type 2 diabetes)

Dysesthesia develops over weeks and may persist

Some patients might find savings offers to help reduce the expense

To understand who qualifies for treatment and when clinician review is essential, see our guide on Who Is Eligible for Weight Loss Injections in the UK

Sreekantaiah C, Ladanyi M, Rodriguez E, Chaganti RSK